Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Endostatin is known to inhibit angiogenesis and tumor growth.
• The function of its precursor, collagen XVIII, in human cancer, particularly hepatocellular carcinoma (HCC), remains unclear.
• Collagen XVIII has short and long variants; the long form is predominantly expressed by liver hepatocytes.

Purpose of the Study:

• To investigate the role of endogenous collagen XVIII in hepatocellular carcinoma (HCC).
• To determine the relationship between collagen XVIII expression levels and tumor progression markers, including angiogenesis.

Main Methods:

• Analysis of RNA arrays from 57 HCCs using common and variant-specific probes.
• Measurement of CD34-positive microvessel density to assess angiogenesis.
• Correlation analysis between collagen XVIII expression and clinicopathological features like tumor size, architecture, and recurrence.

Main Results:

• Low collagen XVIII expression in tumor hepatocytes correlated with larger tumor size and advanced tumor architecture.
• Tumors with higher collagen XVIII levels exhibited smaller size and reduced microvessel density compared to those with moderate levels.
• Decreased collagen XVIII mRNA levels were observed in HCCs recurring within 2 years post-resection.
• The findings were specifically linked to the hepatocyte-specific long form of collagen XVIII.

Conclusions:

• Endogenous collagen XVIII expression decreases with tumor progression in HCC.
• Reduced collagen XVIII is associated with increased angiogenesis in primary liver cancer.
• These findings highlight a potential tumor-suppressive role for collagen XVIII in HCC.